{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:27:33Z","timestamp":1793842053239,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018254","name":"Japanese Foundation for Research and Promotion of Endoscopy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 21K09380"],"award-info":[{"award-number":["JP 21K09380"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 22K16809"],"award-info":[{"award-number":["JP 22K16809"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euo.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T20:36:32Z","timestamp":1707165392000},"page":"1338-1349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"7","author":[{"given":"Keisuke","family":"Shigeta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Kitaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minami","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishiro","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yota","family":"Yasumizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.01.013_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupret","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.01.013_b0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.01.013_b0015","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.01.013_b0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrurol.2017.190","article-title":"Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition","volume":"15","author":"Siefker-Radtke","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2024.01.013_b0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2024.01.013_b0030","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.01.013_b0035","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.01.013_b0040","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2024.01.013_b0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.01.013_b0050","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2008.17.2361","article-title":"Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma","volume":"27","author":"Kikuchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.01.013_b0055","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41416-021-01559-8","article-title":"Landscape of prognostic signatures and immunogenomics of the AXL\/GAS6 axis in renal cell carcinoma","volume":"125","author":"Hakozaki","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2024.01.013_b0060","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/bjc.2012.314","article-title":"Expression and prognostic significance of Src family members in renal clear cell carcinoma","volume":"107","author":"Qayyum","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2024.01.013_b0065","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00262-022-03250-0","article-title":"A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer","volume":"72","author":"Rijnders","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euo.2024.01.013_b0070","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1007\/s00262-022-03204-6","article-title":"Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis","volume":"71","author":"Yoshida","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euo.2024.01.013_b0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signaling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2024.01.013_b0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.01.013_b0085","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2024.01.013_b0090","doi-asserted-by":"crossref","first-page":"1178337","DOI":"10.3389\/fimmu.2023.1178337","article-title":"The generation, activation, and polarization of monocyte-derived macrophages in human malignancies","volume":"14","author":"Chaintreuil","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.euo.2024.01.013_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","article-title":"Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis","volume":"21","author":"Koll","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.euo.2024.01.013_b0100","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s43018-023-00548-5","article-title":"The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer","volume":"4","author":"Kraemer","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.euo.2024.01.013_b0105","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.01.013_b0110","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2024.01.013_b0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.01.013_b0120","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1245\/s10434-016-5354-5","article-title":"High absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy","volume":"23","author":"Shigeta","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euo.2024.01.013_b0125","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cas.13476","article-title":"Tumor-associated CD204(+) M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma","volume":"109","author":"Kawachi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.euo.2024.01.013_b0130","first-page":"170","article-title":"Recruitment of monocytes\/macrophages in different tumor microenvironments","volume":"1835","author":"Lee","year":"2013","journal-title":"Biochim Biophys Acta"}],"updated-by":[{"DOI":"10.1016\/j.euo.2025.04.023","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}},{"DOI":"10.1016\/j.euo.2026.10.012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:00:00Z","timestamp":1793836800000}}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T19:10:53Z","timestamp":1737832253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124000397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2588931124000397"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.01.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}